| Literature DB >> 32992919 |
Mona M Ismail1, Badriyah S Alotaibi2, Mostafa M El-Sheekh3.
Abstract
Red Seaweed "Rhodophyta" are an important group of macroalgae that include approximately 7000 species. They are a rich source of structurally diverse bioactive constituents, including protein, sulfated polysaccharides, pigments, polyunsaturated fatty acids, vitamins, minerals, and phenolic compounds with nutritional, medical, and industrial importance. Polysaccharides are the main components in the cell wall of red algae and represent about 40-50% of the dry weight, which are extensively utilized in industry and pharmaceutical compounds, due to their thickening and gelling properties. The hydrocolloids galactans carrageenans and agars are the main red seaweed cell wall polysaccharides, which had broad-spectrum therapeutic characters. Generally, the chemical contents of seaweed are different according to the algal species, growth stage, environment, and external conditions, e.g., the temperature of the water, light intensity, nutrient concentrations in the ecosystem. Economically, they can be recommended as a substitute source for natural ingredients that contribute to a broad range of bioactivities like cancer therapy, anti-inflammatory agents, and acetylcholinesterase inhibitory. This review touches on the main points of the pharmaceutical applications of red seaweed, as well as the exploitation of their specific compounds and secondary metabolites with vital roles.Entities:
Keywords: Rhodophyta; bioactive compounds; drugs; seaweed
Mesh:
Substances:
Year: 2020 PMID: 32992919 PMCID: PMC7583832 DOI: 10.3390/molecules25194411
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Photo of common red seaweed species with potential from Egypt coasts.
Figure 2The viral infection stages and the antiviral potency of macroalgal polysaccharides, modified after [21].
Figure 3Graphical illustrating the antioxidant activities of macroalgal phenolic compounds toward the harmful impacts related to the hyperglycemia [6].
Figure 4TLC qualitative AChEI assay. PC: +ve control, physostigmine (0.03 μg). DCM/MeOH extracts (100 μg) of (1) Hypnea musciformis, (2) Pterocladia capillacea, and (3) Ochtodes secundiramea. TLC elution system: hexane:ethyl acetate:methanol (2:7:1 v/v/v) [89].